Zydus' Nesher Pharma gets USFDA nod to market Oseltamivir as influenza drug

Prof Dr,DRAM,HIV /AIDS,HEPATITIS ,SEX DISEASES & WEAKNESS expert,New Delhi,India, +917838059592

Drug firm Zydus Cadila said Nesher Pharmaceuticals, a subsidiary of its US arm, has received final approval from the US health regulator to market Oseltamivir (Tamiflu) used for treatment and prevention of influenza.Oseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate. The proposed mechanism of action of oseltamivir is inhibition of influenza virus neuraminidase with the possibility of alteration of virus particle aggregation and release.

            Tamiflu (oseltamivir) is an antiviral medication that blocks the actions of influenza virus types A and B in your body. Tamiflu is used to treat influenza in people 2 weeks of age and older who have had flu symptoms for 2 days or less.The typical flu incubation period is between 24 hours and 4 days, with the average being 2 days. What this means is that if you are exposed to the influenza virus and become infected, you will start to experience flu symptoms anywhere between 24 hours and 4 days after the exposure

                     "Zydus' Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA has received final approval from the USFDA to market Oseltamivir powder for oral suspension, 6 mg/ml...", Zydus  Cadila said in a statement.

                  The product is used in the treatment and prevention of influenza, it added.

                  The drug will be produced at Nesher Pharmaceuticals' manufacturing facility located at St Louis, US, Zydus Cadila said.

                                  The group now has more than 150 approvals and has so far filed over 300 Abbreviated New Drug Applications (ANDAs) since the commencement of the company's filing process.